Genome & Company announced on the 11th that its cosmetics brand "Yuyk" has launched a large-scale campaign, revealing a new campaign video for 2025 featuring the exclusive model RIIZE. The "Sun Lover" campaign, centered on sun care products, expressed the members of RIIZE enjoying the sun even while traveling, portrayed through a sensory visual aesthetic. Notably, the teaser video for the campaign, released on the 1st, captured attention with a fresh and clean mood, trending on social media. Starting with this campaign launch, Yuyk plans to strategically target the sun care market through large-scale outdoor advertising in the Seongsu-dong area of Seoul beginning on the 12th. Additionally, from the 25th to May 1, it will enhance customer engagement through a standalone pop-up store "Yuyk in Seongsu (My Microbiome Exhibition)".
Celltrion announced on the 11th that it will implement the "Celltrion Incheon Regional Commercial Vitalization Project" to activate the sluggish domestic market and realize corporate values of coexistence. The company provided consumption coupons usable at 107 business sites operated by small businesses, such as restaurants and cafes, in the Incheon area where it is headquartered to about 3,000 employees. The total value of the coupons exceeds 600 million won. Celltrion expects that employees can more conveniently use the nearby business sites by utilizing the coupons they received, while also contributing to energizing the local commercial sector affected by declining consumption.
Yuhan Corporation announced on the 11th that it will launch a new over-the-counter product for the improvement of prostate enlargement, "Caripoman Soft Capsule." Prostatic hyperplasia, known as prostate enlargement, is a common urinary-related condition in middle-aged and older men. Many people mistakenly regard it as a natural phenomenon associated with aging and thus neglect it, which may lead to complications such as loss of bladder function, renal damage, bladder stones, and urinary tract infections. The "Caripoman Soft Capsule" is an over-the-counter medication approved by the Ministry of Food and Drug Safety for the improvement of urinary disorders caused by prostatic hyperplasia. Its active ingredient, Cucurbit Seed Oil Extract, suppresses the production of DHT (dihydrotestosterone), the main cause of prostatic hyperplasia, and helps improve urinary symptoms. It can be purchased at pharmacies without a prescription, at a dosage of 1 capsule twice daily.
Huons announced on the 11th that it has simultaneously obtained AEO certification in both export and import sectors following the results of the "2025 1st Export-Import Safety Management Excellent Company (AEO) Review Committee." AEO certification is an international standard recognized in the international community centered around the World Customs Organization (WCO), granted by the customs authorities of each country. The Korea Customs Service reviews compliance with laws, internal control systems, financial soundness, and safety management levels of export and import corporations before awarding certification. Benefits include reduced inspection ratios for imported and exported goods, exclusion from planning and corporate audits, and exemption from collateral provision when declaring imports, which are expected to provide practical assistance for management stability. Additionally, AEO post-management and consulting and support services regarding customs administration challenges are available from advisory specialists.
HLB Genex announced on the 11th that it secured equity in the intractable brain disease treatment developer "HLB Neurotov," integrating it as a subsidiary. HLB will acquire 523,409 common shares and redeemable convertible preferred shares (RCPS) of HLB Neurotov for 16.1 billion won. Through this, it will secure 74.73% equity of HLB Neurotov, becoming the largest shareholder. HLB Neurotov is led by Professor Kim Dae-soo from the Korea Advanced Institute of Science and Technology (KAIST), an expert in brain science. Currently, it is developing treatments for intractable neurological diseases such as NT-1 dystonia and NT-3 Parkinson's disease, with the goal of entering domestic clinical trials for NT-1 by the end of this year.
T&R Biofab announced on the 11th that the efficacy of treatment using "patient-specific artificial bones" made with its 3D printing technology has been demonstrated in clinical research for the treatment of orbital fractures. The company explained that research conducted by a team of ophthalmology professors at Asan Medical Center, Seoul, involving 40 patients from 2019 to 2021 using "patient-specific artificial bones" has been published in the international scientific journal Nature's sister journal, Scientific Reports. Patients were treated with biodegradable implants made from polycaprolactone (PCL), produced using T&R Biofab's 3D printing technology. Pre- and post-surgical CT scans confirmed that the volume difference within the orbit due to fractures had recovered to near normal levels after surgery.
Yuhan Corporation announced on the 11th that after launching a joint promotion for the "Bepanten" ointment and "Canesten" following a domestic supply contract with Bayer Korea in February, it surpassed a total sales volume of 300,000 units for the two products at pharmacies within just one month. Bepanten ointment is the first non-steroidal skin inflammation treatment containing dexpanthenol, suitable for all ages, including infants. It can soothe sensitive skin and restore damaged skin barriers, making it applicable for diaper rashes in infants as well as acute and chronic dermatitis, wounds, post-laser treatment recovery, and sunburn applicable to all ages.
AI medtech company Weisen announced on the 11th that it has signed a supply contract for the AI endoscope "Waymed Endo" with Gangnam Ji-In Hospital. Waymed Endo is an AI software medical device that detects abnormal lesions in real-time in conjunction with gastrointestinal endoscopic examination equipment and immediately notifies medical staff. This contract was pursued with the aim of early screening and treatment of gastrointestinal cancer during health checkups through AI endoscopy technology. Gangnam Ji-In Hospital is capable of a wide range of gastrointestinal endoscopic treatments, from health checkups to polypectomy and early gastric and colorectal cancer endoscopic resection (ESD).
Yuyu Pharma announced on the 11th that it will acquire 471,142 shares of its own stock, equivalent to 2 billion won. Currently, Yuyu Pharma has secured approximately 850,000 shares of common stock. Following this acquisition of its own stock, it will hold 7.8% of the total issued common stock as treasury stock. Yuyu Pharma stated that the acquisition of its own stock is "part of a policy to enhance shareholder value."
Seoul National University Hospital announced on the 11th that Professor Shin Dong-yeob from the Department of Hematology and Oncology has received the Mid-Career Researcher Award at the International Congress of the Korean Society of Hematology (ICKSH2025). The Mid-Career Researcher Award is given to an outstanding researcher who has contributed to the advancement of hematology in Korea and the health and welfare of humanity. Professor Shin received this award for announcing the research study, "Identification of the Mechanism of Bone Destructive Lesion Occurrence in Multiple Myeloma," as the first author in January of last year. This study identified promising biomarkers for multiple myeloma and presented the possibility for improving prognosis, conducted in collaboration with a team of Seoul National University Hospital's Professor Yoon Seung-soo, Sookmyung Women's University Professor Kim Yong-hwan, and Seoul National University Professor Hwang Dae-hee.